{"result": "(\"entity\"<|>FEOCROMOCITOMA<|>EVENT<|>Feocromocitomas are rare tumors that occur in less than 0.2% of patients with hypertension, often associated with familial syndromes and can be bilateral in nature.)\n##\n(\"entity\"<|>PARAGANGLIOMA<|>EVENT<|>Paragangliomas are tumors related to the nervous system, often associated with feocromocitomas and can also be hereditary.)\n##\n(\"entity\"<|>SÍNDROME DE VON HIPPEL-LINDAU<|>EVENT<|>Von Hippel-Lindau syndrome is an autosomal dominant disorder characterized by the presence of feocromocitomas, paragangliomas, and other tumors, with a prevalence of 1 in 35,000 people.)\n##\n(\"entity\"<|>NEOPLASIA ENDOCRINA MÚLTIPLE DE TIPO 2<|>EVENT<|>Multiple endocrine neoplasia type 2 is a hereditary condition that increases the risk of developing feocromocitomas, with a 50% association rate.)\n##\n(\"entity\"<|>NEUROFIBROMATOSIS TIPO 1<|>EVENT<|>Neurofibromatosis type 1 is a genetic disorder that can be associated with feocromocitomas, though less commonly than the other syndromes mentioned.)\n##\n(\"entity\"<|>GENES DE SUSCEPTIBILIDAD<|>EVENT<|>Genes of susceptibility associated with feocromocitomas and paragangliomas have been identified, with 15 genes described since 1990.)\n##\n(\"entity\"<|>VHL<|>PERSON<|>VHL is a tumor suppressor gene located on chromosome 3p25-26, which regulates hypoxia-induced proteins and is associated with Von Hippel-Lindau syndrome.)\n##\n(\"entity\"<|>RET<|>PERSON<|>RET is a gene associated with multiple endocrine neoplasia type 2, which increases the risk of feocromocitomas.)\n##\n(\"entity\"<|>SDHx<|>PERSON<|>SDHx refers to a group of genes (SDHB, SDHC, SDHD) that are associated with hereditary paragangliomas and feocromocitomas.)\n##\n(\"entity\"<|>TMEM127<|>PERSON<|>TMEM127 is a gene associated with susceptibility to feocromocitomas and paragangliomas.)\n##\n(\"entity\"<|>MAX<|>PERSON<|>MAX is a gene that is part of the group associated with hereditary feocromocitomas and paragangliomas.)\n##\n(\"relationship\"<|>FEOCROMOCITOMA<|>SÍNDROME DE VON HIPPEL-LINDAU<|>Feocromocitomas are frequently present in patients with Von Hippel-Lindau syndrome, occurring in 10-20% of cases.<|>8)\n##\n(\"relationship\"<|>FEOCROMOCITOMA<|>NEOPLASIA ENDOCRINA MÚLTIPLE DE TIPO 2<|>Feocromocitomas are commonly associated with multiple endocrine neoplasia type 2, with a 50% occurrence rate.<|>8)\n##\n(\"relationship\"<|>FEOCROMOCITOMA<|>NEUROFIBROMATOSIS TIPO 1<|>Feocromocitomas can occur in patients with neurofibromatosis type 1, although less frequently than in other syndromes.<|>3)\n##\n(\"relationship\"<|>FEOCROMOCITOMA<|>PARAGANGLIOMA<|>Feocromocitomas and paragangliomas are related tumors, often discussed together in the context of hereditary syndromes.<|>7)\n##\n(\"relationship\"<|>VHL<|>FEOCROMOCITOMA<|>The VHL gene is associated with the development of feocromocitomas in patients with Von Hippel-Lindau syndrome.<|>9)\n##\n(\"relationship\"<|>RET<|>FEOCROMOCITOMA<|>The RET gene is linked to the increased risk of feocromocitomas in patients with multiple endocrine neoplasia type 2.<|>8)\n##\n(\"relationship\"<|>SDHx<|>FEOCROMOCITOMA<|>Mutations in the SDHx genes are associated with hereditary feocromocitomas and paragangliomas.<|>8)\n##\n(\"relationship\"<|>TMEM127<|>FEOCROMOCITOMA<|>TMEM127 is a gene that contributes to the susceptibility of developing feocromocitomas.<|>7)\n##\n(\"relationship\"<|>MAX<|>FEOCROMOCITOMA<|>MAX is involved in the genetic predisposition to feocromocitomas and paragangliomas.<|>7)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: , pudiendo detectar tumores no detectados\n                                                                                                        en TAC/RMN. La sensibilidad de la MIBG varía entre el 85% y el 88% en feocromocitomas\n                                                                                                        y  entre el   56%   y  el 75%    en paragangliomas,        pero   tiene   una especificidad       mayor    que\n    COMENTARIO                                                                                          TAC/RMN, llegando         a ser   hasta   del 95-100%. Es útil realizarla en pacientes en los que\n    Los feocromocitomas son neoplasias infrecuentes que probablemente suponen menos de                  no se ha localizado el tumor con TAC/RMN, en caso de lesiones dudosas en TAC/RMN y\n    0,2% de los pacientes con hipertensión.                                                             en aquellos con riesgo aumentado de enfermedad metastásica, como en tumores de gran\n                                                                                                        tamaño, lesión extraadrenal o sospecha de multifocalidad (casos hereditarios), así como en\n    La mayoría de los feocromocitomas son esporádicos; sin embargo, aproximadamente                 el  enfermedad recurrente y para planificación de radioterapia con 131I-MIBG.\n    40% de los pacientes tienen su enfermedad en el contexto de un síndrome familiar. En                La captación de MIBG puede estar disminuida en tumores necróticos y con el uso de simpa-\n    ese caso, los tumores se presentan a edades más tempranas que en los casos esporádicos.             ticomiméticos, antidepresivos tricíclicos, cocaína, calcioantagonistas y labetalol.\n    Hay varios trastornos familiares asociados con feocromocitomas suprarrenales, todos                 La PET con fluorodesoxiglucosa se considera más                    sensible que con MIBG y         TAC/RMN\n    ellos con una herencia autosómica dominante: síndrome de Von Hippel-Lindau, neoplasia               para el diagnóstico de metástasis de un paraganglioma maligno.\n    endocrina múltiple de tipo 2 y menos habitualmente la neurofibromatosis tipo 1.\n    La frecuencia de feocromocitoma asociado en estos trastornos es del 10-20% en el síndro-            La inmunohistoquímica para SDHB de la pieza histológica puede servir para descartar\n    me de Von Hippel-Lindau, del 50% en la neoplasia endocrina múltiple de tipo 2 y del 3% en           mutaciones en SDHB, SDHC y SDHD, ya que, en caso de mutaciones en línea germinal, los\n    la neurofibromatosis de tipo 1.                                                                     tumores presentan una tinción ausente o en patrón difuso débil. La presencia de tinción\n                                                                                                        orienta a la presencia de otras posibles mutaciones.\n    Además, desde 1990 se han descrito 15 genes de susceptibilidad asociados a feocro-                  Si un paciente presenta un feocromocitoma bilateral que no está asociado a carcinoma\n    mocitomas y paragangliomas. Esos genes se han agrupado en dos grupos en función                     medular de tiroides o bocio, el estudio genético debería comenzar con                      VHL, RET, SDHx,\n    de la señal de transcripción que se afecta. De esta manera, tenemos un primer grupo que             TMEM127 y MAX. El fenotipo bioquímico (suprarrenal en MEN2 o no adrenérgico en VHL\n    afecta a genes que codifican proteínas involucradas en la respuesta a la hipoxia y un se-           también puede ser de utilidad para orientar el estudio genético.\n    gundo grupo relacionado con proteínas activadoras de la señal de quinasa. El primer grupo\n    se relaciona con paragangliomas extraadrenales con la excepción del síndrome de Von                 La enfermedad de Von Hippel-Lindau es un trastorno autosómico dominante caracterizado\n    Hippel-Lindau (los tumores suelen localizarse en la suprarrenal) y el segundo grupo se rela-        por la presencia de feocromocitomas (con frecuencia bilateral), paragangliomas, angiomas\n\n\n\n                                                                                                                                                                                                                          309\n---\n     retinianos, hemagioblatomas cerebelosos, cistoadenoma epidídimico, quistes pancreáti-\n     cos    y  renales y       carcinoma renal.           El  feocromocitoma             se   produce      en    alrededor      del 10-20%\n     de los pacientes con enfermedad de Von Hippel-Lindau. La prevalencia del síndrome es\n     de 1 de cada 35.000 personas. El gen supresor tumoral                                    VHL, localizado en el cromosoma\n     3p25-26,       codifica una proteína             que regula proteínas inducidas                  por hipoxia. Casi el 100% de\n     los pacientes\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}